JPH0543350B2 - - Google Patents

Info

Publication number
JPH0543350B2
JPH0543350B2 JP60070392A JP7039285A JPH0543350B2 JP H0543350 B2 JPH0543350 B2 JP H0543350B2 JP 60070392 A JP60070392 A JP 60070392A JP 7039285 A JP7039285 A JP 7039285A JP H0543350 B2 JPH0543350 B2 JP H0543350B2
Authority
JP
Japan
Prior art keywords
additive
cells
cell culture
medium
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP60070392A
Other languages
Japanese (ja)
Other versions
JPS61227780A (en
Inventor
Hiroshi Maeda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP60070392A priority Critical patent/JPS61227780A/en
Publication of JPS61227780A publication Critical patent/JPS61227780A/en
Publication of JPH0543350B2 publication Critical patent/JPH0543350B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Description

【発明の詳細な説明】 産業上の利用分野 本発明は細胞培養技術において、細胞培養用培
地に添加使用される添加剤、詳しくは良好な細胞
培養条件を設定できる新しい細胞培養用添加剤に
関する。
DETAILED DESCRIPTION OF THE INVENTION Field of Industrial Application The present invention relates to an additive used in a cell culture medium in cell culture technology, and specifically relates to a new cell culture additive that can set favorable cell culture conditions.

従来の技術 近年の生物工学の進歩に伴つて、その基礎技術
としての細胞培養技術はますます重要性をまして
きており、特に細胞培養に適した培地について多
くの研究がなされている。
BACKGROUND OF THE INVENTION With recent advances in biotechnology, cell culture technology as a basic technology has become increasingly important, and much research has been carried out particularly on media suitable for cell culture.

現在、かかる細胞培養用培地(栄養培地、基礎
培地)は、種々市販されているが、一般に知られ
ている通り該培地には牛胎児血清(FCS)の添加
が必要である。しかしながら、牛胎児血清は、入
手が困難で且つ高価であり、しかも培養に与える
効果が不均一であるという欠点を有している。ま
た上記牛胎児血清を添加した培地を利用して細胞
培養によつて、有用物質を産生させ採取する場
合、培養液中には上記牛胎児血清に由来する未知
成分を含む極めて多様な成分が混入し、これと目
的とする有用物質との分離が非常に困難となる場
合があり、ときには目的物質の単離が不可能な場
合さえある。
Currently, various types of such cell culture media (nutrient media, basal media) are commercially available, but as is generally known, these media require the addition of fetal calf serum (FCS). However, fetal bovine serum has the drawbacks of being difficult and expensive to obtain, and having uneven effects on culture. In addition, when useful substances are produced and collected by cell culture using a medium supplemented with fetal bovine serum, the culture solution contains an extremely wide variety of components, including unknown components derived from the fetal bovine serum. However, it may be very difficult to separate this from the target useful substance, and sometimes it may even be impossible to isolate the target substance.

一方、牛血清(胎児血清を除く、以下同じ)
は、容易に、安価に且つ大量に入手できるが、こ
れには牛胎児血清に見られる如き細胞増殖を支持
する作用はない。
On the other hand, bovine serum (excluding fetal serum, the same applies hereinafter)
Although it is easily available at low cost and in large quantities, it does not have the effect of supporting cell proliferation as seen in fetal bovine serum.

発明が解決しようとする問題点 本発明は、上記のように細胞増殖作用を有し、
細胞培養用培地への添加が必須である反面、その
利用によれば種々の欠点が伴われる牛胎児血清に
代替え使用でき、しかも該牛胎児血清に見られる
如き欠点を伴わない新しい細胞培養用添加剤を提
供することを目的とする。
Problems to be Solved by the Invention The present invention has a cell proliferation effect as described above,
A new cell culture additive that can be used in place of fetal bovine serum, which must be added to cell culture media but has various drawbacks, and which does not have the drawbacks of fetal bovine serum. The purpose is to provide a drug.

問題点を解決するための手段 上記目的は、牛血清を80〜100℃の温度で加熱
処理して得られる処理上清(以下これを「BS−
sup」という)であつて、カルボキシメチルセル
ロースカラムを用いたイオン交換クロマトグラフ
イーにおいてPH4.5、5.0及び6.0(0.1M酢酸−酢酸
ソーダ緩衝液)に溶出する画分の少なくとも1種
を含有することを特徴とする細胞培養用添加剤に
より達成される。
Means for Solving the Problems The above purpose is to obtain a treated supernatant obtained by heat-treating bovine serum at a temperature of 80 to 100℃ (hereinafter referred to as
sup"), and contains at least one fraction that elutes at pH 4.5, 5.0, and 6.0 (0.1M acetic acid-sodium acetate buffer) in ion exchange chromatography using a carboxymethylcellulose column. This is achieved by a cell culture additive characterized by the following.

本発明細胞培養用添加剤の有効成分物質は、細
胞の機能を保持し、その増殖を極めて良好に促進
する作用を有している。またこれは加熱処理によ
つて不要成分を沈澱として析出させ、除去したも
のであるため、有用物質を産生する細胞の培養用
培地に添加利用する際、不純物の混入が防止さ
れ、有用物質の単離がより容易となる利点があ
り、微生物汚染の問題も回避できる。更に該有効
成分物質は、培養に与える効果が均一である特徴
を有しており、これらのことから、特に培養細胞
を用いて各種薬剤等の細胞毒性を試験する場合等
において殊に有効に利用できる。
The active ingredient of the cell culture additive of the present invention has the effect of maintaining cell functions and promoting cell proliferation extremely well. In addition, since unnecessary components are precipitated and removed through heat treatment, when added to the culture medium of cells that produce useful substances, contamination with impurities is prevented and useful substances are isolated. It has the advantage of being easier to separate, and the problem of microbial contamination can also be avoided. Furthermore, the active ingredient has the characteristic that it has a uniform effect on culture, and for these reasons, it can be used particularly effectively when testing the cytotoxicity of various drugs using cultured cells. can.

本発明細胞培養用添加剤においては、上記BS
−supであつてカルボキシメチルセルロースカラ
ムを用いたイオン交換クロマトグラフイーにおい
て0.1M酢酸−酢酸ソーダ緩衝液にて設定したPH
4.5、5.0及び6.0にそれぞれ溶出することで特徴づ
けられる画分(以下これらを各々「F−1」、「F
−2」及び「F−3」という)のいずれかを単独
で又はその2種以上を有効成分として含有させて
もよく、更にこれらの有効成分をすべて含有する
上記BS−supをそのまま利用することもできる。
In the cell culture additive of the present invention, the above BS
-sup and pH set in 0.1M acetic acid-sodium acetate buffer in ion exchange chromatography using a carboxymethyl cellulose column.
Fractions characterized by eluting at 4.5, 5.0, and 6.0 (hereinafter referred to as "F-1" and "F-1", respectively)
-2" and "F-3") may be contained alone or in combination of two or more thereof as an active ingredient, and furthermore, the above BS-sup containing all of these active ingredients may be used as is. You can also do it.

以下、本発明細胞培養用添加剤をその製造法よ
り詳述する。
The cell culture additive of the present invention will be described in detail below, starting with its manufacturing method.

本発明添加剤の製造において用いられる牛血清
としては、各種の市販品を利用することもでき、
また常法に従い牛より採血した血液もしくは屠殺
場にて得た血液より常法に従い分離精製したもの
を利用することもできる。
As the bovine serum used in the production of the additive of the present invention, various commercially available products can be used.
It is also possible to use blood collected from cows or blood obtained at a slaughterhouse, separated and purified in a conventional manner.

上記牛血清の加熱処理は、牛血清そのもの又は
必要に応じてこれを適当な水性溶媒、例えば生理
食塩水、リン酸塩緩衝液等の通常の緩衝液等で希
釈した希釈液を、80〜100℃、好ましくは約85〜
90℃で約20〜30分程度加熱することにより実施さ
れる。
The above heat treatment of bovine serum can be carried out by diluting the bovine serum itself or, if necessary, diluting it with an appropriate aqueous solvent, such as a normal buffer such as physiological saline or phosphate buffer, at a temperature of 80 to 100%. ℃, preferably about 85 ~
This is carried out by heating at 90°C for about 20 to 30 minutes.

上記加熱処理によれば沈澱物が析出し、これを
除去することにより本発明のBS−supが収得され
る。この沈澱物の除去は常法に従い、例えば
過、遠心分離法等により行なうことができる。
According to the above heat treatment, a precipitate is deposited, and by removing this precipitate, the BS-sup of the present invention is obtained. Removal of this precipitate can be carried out according to conventional methods, such as filtration or centrifugation.

また上記BS−supの精製物としてのF−1、F
−2及びF−3は、通常のイオン交換体を用いる
イオン交換クロマトグラフイー、分子ふるいクロ
マトグラフイー等の一般的な物理的、生化学的操
作に従い、BS−supを適宜処理することにより収
得され、上記画分として特定される。
In addition, F-1 and F as purified products of the above BS-sup
-2 and F-3 are obtained by appropriately treating BS-sup according to general physical and biochemical operations such as ion exchange chromatography using a normal ion exchanger and molecular sieve chromatography. and identified as the above fraction.

斯くしてBS−sup、F−1、F−2及びF−3
の各々が収得され、これらは必要に応じて更に透
析等の通常の精製手段や凍結乾燥処理等に付すこ
とができる。
Thus BS-sup, F-1, F-2 and F-3
are obtained, and these can be further subjected to conventional purification means such as dialysis, freeze-drying, etc., as necessary.

本発明の細胞培養用添加剤は、上記のごとくし
て得られる有効成分(BS−sup、F−1、F−2
及びF−3)を効果的に含有する限り、その形態
等に特に制限はなく、例えば有効成分のみを含む
水性溶媒溶液の形態のまま、本発明所期の細胞培
養用添加剤として有利に利用できる。
The cell culture additive of the present invention contains the active ingredients (BS-sup, F-1, F-2) obtained as described above.
As long as it effectively contains F-3), there is no particular restriction on its form, for example, it can be advantageously used as the cell culture additive of the present invention in the form of an aqueous solvent solution containing only the active ingredient. can.

また本発明の添加剤には、通常の希釈剤、栄養
培地の成分、増殖支持成分、保存剤等を添加配合
させておくこともでき、本発明はかかる希釈剤等
の添加剤を配合した形態のものも、当然に包含す
る。
Further, the additive of the present invention can be blended with a usual diluent, a component of a nutrient medium, a growth supporting component, a preservative, etc., and the present invention provides a form in which additives such as such a diluent are blended. Naturally, it also includes those of

本発明の添加剤は、これを一般の細胞培養用基
礎培地に添加して細胞培養に利用できる。上記基
礎培地としては、特に限定はなく公知の各種のも
のをいずれも使用できる。その具体例としては、
例えばRITC培地、CEM培地、CMRL−1066培
地、DM−160培地、イーグルの最小必須培地
(Eagle′s MEM)、オートクレーブ可能MEM、
フイシヤーの培地(Fisher′s Medium)、F−10
培地、F−12培地、L−15培地、NCTC−109培
地、RPMI−1640培地等を例示できる。
The additive of the present invention can be used for cell culture by adding it to a general basal medium for cell culture. The above-mentioned basal medium is not particularly limited, and any known variety can be used. As a specific example,
For example, RITC medium, CEM medium, CMRL-1066 medium, DM-160 medium, Eagle's minimum essential medium (Eagle's MEM), autoclavable MEM,
Fisher's Medium, F-10
Examples of the medium include F-12 medium, L-15 medium, NCTC-109 medium, and RPMI-1640 medium.

本発明添加剤の上記培地に対する添加量は、任
意に決定でき、特に限定はないが、通常培地1ml
に対して有効成分とするBS−sup又はF−1、F
−2及びF−3の少なくとも一種がその総蛋白量
で0.1μg〜100μg程度、好ましくは1〜30μg程
度となる量とするのがよい。
The amount of the additive of the present invention to be added to the above medium can be arbitrarily determined and is not particularly limited, but the amount of the additive of the present invention added to the above medium can be determined arbitrarily.
BS-sup or F-1, F as an active ingredient for
The total protein amount of at least one of -2 and F-3 is about 0.1 μg to 100 μg, preferably about 1 to 30 μg.

上記本発明添加剤を添加された細胞培養用培地
を用いて細胞を培養する方法は、従来の細胞培養
方法と特に異なるところはなく、培養すべき細胞
の増殖に適した適当なPH及び温度条件下、通常PH
6〜8及び温度約37℃前後で培養を行なえばよ
い。
The method of culturing cells using the cell culture medium to which the additive of the present invention has been added is not particularly different from conventional cell culture methods, and requires appropriate pH and temperature conditions suitable for the growth of the cells to be cultured. Lower, normal PH
The culture may be carried out at a temperature of about 6 to 8°C and a temperature of about 37°C.

本発明細胞培養用添加剤を添加利用した培地を
用いて培養できる細胞は、特に制限はないが、動
物由来の細胞であるのが好ましい。該細胞は、付
着性細胞でも、浮遊性細胞でもよく、またすでに
株化された細胞でも、新鮮な悪性腫瘍細胞や正常
細胞でもよく、いずれの細胞でも本発明添加剤を
添加した培地での培養により良好な増殖が認めら
れる。
Cells that can be cultured using a medium supplemented with the cell culture additive of the present invention are not particularly limited, but cells of animal origin are preferred. The cells may be adherent cells or floating cells, or may be already established cell lines, fresh malignant tumor cells, or normal cells, and any of these cells may be cultured in a medium supplemented with the additive of the present invention. Good proliferation is observed.

実施例 以下、本発明を更に詳しく説明するため実施例
及び試験例を挙げる。
Examples Examples and test examples are given below to explain the present invention in more detail.

実施例 1 リン酸塩緩衝生理食塩液(PBS、PH=7.4)
にて2倍希釈した牛血清100mlを水浴中で90℃、
30分間加熱した。加熱終了後、反応液を遠心分
離(5000rpm×30分)して上清を得た。この上
清をPBSに対して一晩透析後、10mg蛋白量/
mlに調製した。これを「添加剤No.1」とする。
Example 1 Phosphate buffered saline (PBS, PH=7.4)
100 ml of bovine serum diluted 2 times at 90℃ in a water bath.
Heat for 30 minutes. After heating, the reaction solution was centrifuged (5000 rpm x 30 minutes) to obtain a supernatant. After dialyzing this supernatant against PBS overnight, 10 mg protein/
ml. This is called "Additive No. 1".

上記で得た上清を、CM−52カラム
〔Whatman;径1.6×40cm、溶出液;0.1M酢酸
−酢酸ソーダ緩衝液、3ml/チユーブ〕に付
し、PH4.5、5.0及び6.0の各PHの溶出画分を得、
これらを各々1.0mg蛋白量/mlに調製した。こ
れらを順次「添加剤No.2」、「添加剤No.3」及び
「添加剤No.4」とする。
The supernatant obtained above was applied to a CM-52 column [Whatman; diameter 1.6 x 40 cm, eluent: 0.1 M acetic acid-sodium acetate buffer, 3 ml/tube], and the pH was adjusted to 4.5, 5.0, and 6.0. Obtain the elution fraction of
Each of these was adjusted to have a protein content of 1.0 mg/ml. These are sequentially referred to as "Additive No. 2,""Additive No. 3," and "Additive No. 4."

試験例 1 ヒト細胞株HEL〔Human embryonic lung
fibroblast;Kuruse及びPatterson著、Tissue
Culture、p336、Academic Press、
NewYork、1973年版〕を、牛血清アルブミン
(BSA)を除いたRITC培地〔Cell Str.Func.、
1279(1976)〕に、1.0×104細胞/デイツシユに
て接種し、各種濃度の添加剤No.1の存在下に培
養した。6日後に生細胞数を計測した。その結
果を第1図にグラフ(1)として示す。図において
縦軸は細胞数(×104細胞/デイツシユ)を、
横軸は供試薬剤(添加剤)添加量(μg蛋白
量/ml)を示し、この添加量Oはコントロール
を示す。また第1図には対照薬剤としてα1酸性
糖蛋白(AGP)を添加した時の結果をグラフ
(2)として併記する。
Test example 1 Human cell line HEL [Human embryonic lung]
fibroblast; by Kuruse and Patterson, Tissue
Culture, p336, Academic Press,
NewYork, 1973 edition] in RITC medium [Cell Str.Func., without bovine serum albumin (BSA)].
1279 (1976)] at 1.0×10 4 cells/dish and cultured in the presence of additive No. 1 at various concentrations. The number of living cells was counted after 6 days. The results are shown in graph (1) in Figure 1. In the figure, the vertical axis represents the number of cells (×10 4 cells/date).
The horizontal axis represents the amount of the test drug (additive) added (μg protein amount/ml), and this amount O represents the control. Figure 1 also shows the results when α1 acid glycoprotein (AGP) was added as a control drug.
Also listed as (2).

第1図より本発明添加剤の利用によれば細胞
の増殖が極めて顕著となることが明らかであ
る。
It is clear from FIG. 1 that the use of the additive of the present invention results in extremely significant cell proliferation.

上記において、HELの代りにHeLa−S3
〔Human cervical carcinoma;J.E.M.103273
(1956)〕を用い、同様にして本発明添加剤の細
胞増殖活性を試験した。結果は第2図の通りで
あり、本発明添加剤の添加によれば、グラフ(1)
として示す通り、AGPの添加(グラフ(2)に示
す)と対比しても、上記HeLa−S3細胞の増殖
を顕著に促進できることが判る。
In the above, HeLa-S3 instead of HEL
[Human cervical carcinoma; JEM103273
(1956)], the cell proliferation activity of the additive of the present invention was tested in the same manner. The results are shown in Figure 2, and according to the addition of the additive of the present invention, graph (1)
As shown, it can be seen that the proliferation of the HeLa-S3 cells can be significantly promoted even when compared with the addition of AGP (shown in graph (2)).

上記において、HELの代りに吉田肉種
〔Yoshida sarcoma(YS);佐藤博著「日本で
維持されている可移植性腫瘍一覧表(日本癌学
会総会記事別刷)」、第51頁、昭和56年10月(日
本癌学会)〕の1次培養細胞を用い(但し接種
量は1.0×104細胞/mlとした)4日間培養する
以外は同様にして本発明添加剤の細胞増殖活性
を試験した。結果は第3図にグラフ(1)として示
す通りであり、グラフ(2)として示されるAGP
の利用では達成されない良好な細胞増殖活性が
奏されることが確認された。
In the above, Yoshida sarcoma (YS) was used instead of HEL; Hiroshi Sato, "List of transplantable tumors maintained in Japan (Japanese Cancer Society general meeting article reprint)", p. 51, 1982. The cell proliferation activity of the additive of the present invention was tested in the same manner except that the cells were cultured for 4 days using primary cultured cells (inoculated at 1.0 x 10 4 cells/ml) in October (Japan Cancer Society). . The results are shown as graph (1) in Figure 3, and the AGP is shown as graph (2).
It was confirmed that good cell proliferation activity was achieved which cannot be achieved by using .

上記において添加剤No.1の代りに添加剤No.
2、添加剤No.3及び添加剤No.4の各々を接種量
1.0×104細胞/ウエルで用いて同様の試験を行
なつた。結果を第4図に示す。
In the above, additive No. 1 is replaced with additive No. 1.
2. Inoculum amount of each of Additive No. 3 and Additive No. 4
A similar test was performed using 1.0×10 4 cells/well. The results are shown in Figure 4.

図においてグラフ(3)は添加剤No.2の利用を、
グラフ(4)は添加剤No.3の利用を、またグラフ(5)
は添加剤No.4の利用をそれぞれ示す。
In the figure, graph (3) shows the use of additive No. 2.
Graph (4) shows the use of additive No. 3, and graph (5)
indicate the use of additive No. 4, respectively.

第4図より上記各添加剤も添加剤No.1と同様
に優れた細胞増殖活性を有することが判る。
From FIG. 4, it can be seen that each of the above-mentioned additives also has excellent cell proliferation activity similar to Additive No. 1.

【図面の簡単な説明】[Brief explanation of the drawing]

第1図乃至第4図は、それぞれ本発明細胞培養
用添加剤を添加した培地を用いて各種細胞を培養
したときの該細胞の増殖性を調べた結果を示すグ
ラフである。
FIG. 1 to FIG. 4 are graphs showing the results of examining the proliferation properties of various cells when cultured using a medium supplemented with the cell culture additive of the present invention.

Claims (1)

【特許請求の範囲】[Claims] 1 牛血清を80〜100℃の温度で加熱処理して得
られる処理上清であつて、カルボキシメチルセル
ロースカラムを用いたイオン交換クロマトグラフ
イーにおいてPH4.5、5.0及び6.0(0.1M酢酸−酢酸
ソーダ緩衝液)に溶出する画分の少なくとも1種
を含有することを特徴とする細胞培養用添加剤。
1 The treated supernatant obtained by heat-treating bovine serum at a temperature of 80 to 100°C, which has a pH of 4.5, 5.0, and 6.0 (0.1M acetic acid-sodium acetate), was analyzed by ion exchange chromatography using a carboxymethyl cellulose column. An additive for cell culture, characterized in that it contains at least one fraction eluted in a buffer solution.
JP60070392A 1985-04-03 1985-04-03 Additive for cell culture Granted JPS61227780A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP60070392A JPS61227780A (en) 1985-04-03 1985-04-03 Additive for cell culture

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60070392A JPS61227780A (en) 1985-04-03 1985-04-03 Additive for cell culture

Publications (2)

Publication Number Publication Date
JPS61227780A JPS61227780A (en) 1986-10-09
JPH0543350B2 true JPH0543350B2 (en) 1993-07-01

Family

ID=13430124

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60070392A Granted JPS61227780A (en) 1985-04-03 1985-04-03 Additive for cell culture

Country Status (1)

Country Link
JP (1) JPS61227780A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5779882A (en) * 1980-10-31 1982-05-19 Green Cross Corp:The Preparation of blood serum usable in cell cultivation medium

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5779882A (en) * 1980-10-31 1982-05-19 Green Cross Corp:The Preparation of blood serum usable in cell cultivation medium

Also Published As

Publication number Publication date
JPS61227780A (en) 1986-10-09

Similar Documents

Publication Publication Date Title
Burgess et al. Stimulation by human placental conditioned medium of hemopoietic colony formation by human marrow cells
JP2702103B2 (en) Tumor growth inhibitory factor and method for preparing the same
US4404188A (en) Purified Mullerian Inhibiting Substance and method of purification
GB2092159A (en) Process for the production of human colony stimulating factor
FR2461500A1 (en) PROCESS FOR PRODUCING A SUBSTANCE CAPABLE OF STIMULATING THE PROLIFERATION AND DIFFERENTIATION OF HUMAN GRANULOPOIETIC STEM CELLS
JPS58190397A (en) Interrykin 2 and purification thereof
EP0090892B1 (en) Process for the purification of physiologically active substance having antitumour activity
US4510131A (en) Purified Mullerian Inhibiting Substance and method of use
CA1283048C (en) Therapeutic agent for treating hematopoietic diseases
US3122476A (en) Tissue culture medium
DE3643428C2 (en)
JPH0543350B2 (en)
WO1992012177A1 (en) Novel megakaryocyte amplifier and production thereof
DE3539775C2 (en) New lymphokine, antibodies specific to this lymphokine, process for their preparation and their use
JPH0472840B2 (en)
DE3421731A1 (en) Human tumour necrosis factor
CN115992116B (en) Multifunctional dairy cow lysozyme and preparation method and application thereof
KR950008569B1 (en) Novel lymphokine and its production and uses
WO1984002912A1 (en) Protein with oncostatic effect, process for its preparation, and oncostatic drug containing it
JPH0214039B2 (en)
US4613458A (en) Regulatory substance of DNA synthesis
Lumsden et al. Stabilisation and purification of specific anti-cancer bodies
JPS63188697A (en) Cell growth promoting substance extracted from bovine spleen, extraction thereof and inactivation treatment of virus
EP0108919B1 (en) Process for producing t cell-activating factor
KR820001174B1 (en) Process for producing human-specific interferon